Company intelligence / Profile preview
Xi'an Yufan Biotechnology
- Ownership
- Private
- Development stage
- Other
Overview
Xi'an Yufan Biotechnology is a clinical-stage biotech developing next-generation CAR-T therapies. Its lead program is a CRISPR-edited autologous CAR-T targeting CD19 with HPK1 knockout for hematological malignancies in Phase 1 trials. Early data presented at ASCO 2022 showed efficacy and adverse event profiles in precursor cell lymphoblastic leukemia/lymphoma and B-cell lymphoma patients[8]. The company also has preclinical programs targeting BCMA and other cancer antigens using its enhanced CAR-T platform.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapyGene therapySmall moleculeMonoclonal antibody (preclinical/discovery)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Xi'an Yufan Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xi'an Yufan Biotechnology.